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 The Cost of Biotechnology Regulation in the Philippines 
 
 
Modern agricultural biotechnologies, including Genetically Modified (GM) crops, have 
demonstrated their potential to provided significant benefits for developing countries. 
However, many developing countries lack functional and enabling regulatory processes 
that allow the release of GM crops into the environment.  A suitable regulatory process 
has been deemed necessary by international agreements and national governments for the 
safety of those who consume genetically modified organisms (GMOs) as well as for the 
environment that might be affected by these products.  Each nation needs a set of 
regulations that are both protective and efficient.  In setting regulations, countries must be 
cautious but not overly restrictive unless they intend to delay or even forgo the benefits of 
the technology. 
Costs associated with implementing a regulatory process for a specific transgenic 
product can be a significant portion of the total costs of bringing the product to market 
(Jafee 2006; Pray, Bengali, and Ramaswami 2005). Some of these costs involve direct 
expenditures made to comply with biosafety regulations while others are opportunity 
costs of benefits foregone from the product being delayed while advancing through 
regulatory processes needed for commercialization approval. In evaluating the potential 
net benefits of genetically modified crops, it is important to understand the magnitude of 
these costs, both for countries still in the process of designing their regulatory processes, 
and for those implementing their own.  
Regulatory costs vary by country and for conditions specific to each GM event - 
defined as a combination of a specific crop and gene. For example, costs can be affected   3
if certain bio-safety tests for a product have already been conducted in other countries 
and are accepted in an evaluating country, the product has been developed and tested in 
the public versus the private sector, the product will be exported, and the product is 
consumed as a food as opposed to a feed or a fiber product. The products examined in 
this paper: Bt eggplant, Bt rice, ring-spot virus resistant (RVR) papaya, and multiple-
virus resistant (MVR) tomato,  in the Philippines, differ in the amount of previous bio-
safety testing in other countries, in their export status, degree of private versus public 
involvement, and their importance in domestic food consumption. 
 This paper provides background on bio-safety regulatory issues, cost of 
compliance in selected countries, and policy issues faced by developing countries. It 
identifies and estimates the direct costs and opportunity costs of regulation for four 
transgenic products in the Philippines. It provides estimates of changes in economic 
surplus for those crops that incorporate the cost of compliance with bio-safety regulations 
and R&D costs. The implications of delaying the benefit stream due to regulatory delay 
are considered. Finally, lessons are drawn for the Philippines and other developing 
countries with respect to bio-safety issues.  
The paper finds that direct regulatory costs while significant, are similar in 
magnitude or smaller than the research costs for technology development. However, both 
research and regulatory costs are overshadowed by even a relatively short delay in 
product release, which might be caused by an unexpected regulatory delay. The 
opportunity cost of benefits foregone due to non- or delayed approval during a bio-safety 
regulatory assessment are significant, and thus an important issue for debate and   4
reflection in developing countries contemplating the use of GM technologies. 
 
Bio-safety Regulatory Regimes 
During the earliest stages of the discovery and R&D process, the novelty of GM 
organisms led scientists and policy makers to design and implement regulatory processes 
that would ensure proper safety assessments and decision making. Bio-safety processes 
formalized in the Cartagena Protocol on Bio-safety, have now become pre-requisite for 
GM research and release into the environment. The Bio-safety Protocol focused on the 
potential effects of GMOs on the environment. Nevertheless, most bio-safety regulatory 
systems have broadened their scope of action to include food and feed safety and, in 
some cases, other considerations such as socio-economics and ethics. 
Most bio-safety systems are sequential learning processes where the knowledge 
and data accumulated in a regulatory stage are used to decide whether the product 
advances to the next regulatory stage. The data and knowledge may be generated within 
the country or outside it for the specific application or for a related crop (i.e. potatoes and 
sweet potatoes). The task of the decision maker, in this case a national bio-safety 
authority, is to decide whether the data submitted are sufficient to demonstrate an 
established level of safety. 
 
Previous Evidence on Cost of Compliance with Bio-safety Regulations 
Estimates of the cost of compliance with bio-safety regulations in selected countries are 
presented in Table 1. These data do not include the cost of R&D or technology transfer to 
producers. It is clear that the cost of compliance varies across countries, crops, and traits.    5
These estimates do not take into account the time value of money, nor indicate the 
relative importance of the costs of compliance compared to other costs of 
commercializing a new technology in a particular country.  
The total cost of compliance with bio-safety regulations is the sum of a set of 
distinct activities performed during a bio-safety assessment. These activities are 
undertaken to collect or generate data and information that will be used to judge specific 
safety attributes of a particular technology. The total cost of compliance with bio-safety 
regulations for three countries: the United States, India and China, are presented in Table 
2. These cost estimates reflect the diverse philosophies and approaches to regulation in 
the selected countries.  
 
Table 1. Cost of Compliance with the bio-safety regulations in selected countries
1 
Type of Crop 
(example) 
Crop  Country  Event approved in 
Developed Countries 
Estimated Costs of Bio-
safety Regulations (US$) 
Food Crop  Maize  India  Yes  500,000 - 1,500,000 
 Maize  Kenya  Yes 980,000 
 Rice  India  No  1,500,000-  2,000,000 
 Rice  Costa  Rica  No 2,800,00 
 Beans  Brazil  No  700,000 
  Mustard  India  No, have to seek approval 
in export markets 
4,000,000 
 Soybeans  Brazil  Yes  4,000,000 
 Potatoes  South  Africa  Yes  980,000 
 Potatoes  Brazil    980,000 
 Papaya  Brazil  Yes   
Non-Food Crop  Cotton  India  Yes  500,000 - 1,000,000 
  Jute  India  No  1,000,000 - 1,500,000 
1. Compilation presented in Falck Zepeda (2006) based on estimates from Quemada (2004), Odhiambo 
(2003), Sampaio(2002), Sittenfeld(2002), and Pray, Bengali and Ramaswamy (2004). 
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Regulators and the regulatory systems in the three countries may have differing views on 
the data and information needed to demonstrate reasonable safety. Note the smaller costs 
of meeting bio-safety rules in China as compared to India. This difference may also 
reflect assessment cost differences for the public as opposed to the private sector.  
  










Molecular characterization  300,000 – 1,200,000     
Toxicology (90 day rat trial)  250,000 – 300,000    14,500 
Allergenicity (Brown Norwegian rat study)    150,000   
Animal performance and safety studies  300,000 – 840,000     
Poultry feeding study    5,000   
Goat feeding study – 90 days    55,000   
Cow feeding study    10,000   
Fish feeding study    5,000   
Anti-nutrient     1,200 
Gene flow    40,000  11,200 
Impact on non-target organisms      11,600 
Baseline and follow-up resistance studies     20,000   
Protein production/characterization  160,000 – 1,700,000     
Protein safety assessment  190,000 – 850,000     
Non-target organism studies  100,000 – 600,000     
ELISA development, validation, and 
expression 
400,000 – 600,000     
Composition assessment  750,000 – 1,500,000     
Agronomic and phenotypic assessment  130,000 – 460,000  30,000 – 205,000   
Socio-economic studies    15,000 - 30,000   
Facility/management overhead costs  600,000 – 4,500,000     
Total Cost Approval    195,000   
1. Compilation presented in Falck Zepeda (2006) based on estimates for USA by Kalatzaidonakes, Alston 
and Bradford (2005); for India by Pray, Ramaswamy, and Bengali (2004); and for China, Pray et al. (2006).  
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Present value of 
cost (US$) 
Philippines Golden  Rice  IRRI  104,698 
  Bacterial blight resistant rice 
(Xa-21) 
Phil-Rice 99,213 
 Bt  maize  Monsanto  1,690,000 
Indonesia Bt  cotton  Monsanto  99,870 
 Herbicide  resistant  cotton  Monsanto  112,480 
  Bt rice  RCB-IIS / LIPI  64,730 
  Drought tolerant sugarcane  PTPN XI Perseroan Terbatas 
Perkebunan Negara - Government 
Enterprise for Estate Crops 
98,879 
  Transgenic Citrus Resistant to 
CPVD 
Udayana University  Abandoned 
Note: Source: Falck Zepeda (2006). 
 
Methods 
The steps in the regulatory process and its direct costs and timing were defined for the 
Philippines through review of documents and interviews with government officials, 
researchers, and other experts in the regulatory process for biotech products in the 
Philippines. Those interviewed included: (a) scientists and experts from the Institute of 
Plant Breeding at the University of the Philippines Los Baños, The International Rice 
Research Institute, and the Philippine Rice Research Institute, and (b) regulators from the 
Department of Science and from the National Committee on Bio-safety of the Philippines. 
The interviews helped identify circumstances in which bio-safety and other tests 
conducted in other countries are accepted and how that acceptance affects the costs. The 
costs and time associated with each of the following steps were assessed:    8
1.  Preparing a project proposal for submission to the Institutional Bio-safety Committee 
(IBC),  
2.  Submitting a proposal to the IBC which conducts a risk/benefit assessment and then 
submits it to the National Committee on Bio-safety of the Philippines (NCBP),  
3.  NCBP creates a Scientific and Technical Review Panel (STRP) concurrent with public 
notification by the IBC, and the STRP evaluates potential adverse effects to humans 
and the environment, 
4.  Applying to the Bureau of Plant Industry (BPI) for contained testing and incorporation 
of regulated articles, conditional on endorsement by the NCBP,  
5.   Risk assessment by BPI,  
6.  Applying to BPI for a field testing permit after contained testing is complete and 
successful (tests relate to gene flow, food safety, toxicity, efficacy, and other 
environmental tests),  
7.  Single field and then multiple location field testing with each field evaluated 
separately once there is receipt of a field test permit, and 
8.  Obtaining a permit for release for propagation and commercialization.  
 
Each step in the regulatory process allows for increased exposure of the transformed 
product to people and to the environment. A detailed description of the regulatory process 
can be found on the Department of Science and Technology’s NCBP website: 
http://www.ncbp.dost.gov.ph/.  The NCBP is primarily responsible for regulating the 
development and release of transgenic products until the point in the process in which the   9
products have contact with the environment. At that point the regulatory responsibility 
shifts to the Bureau of Plant Industry. 
Once estimates of the costs of these steps were collected, economic surplus 
models were run to evaluate the economic impacts of introducing each of the GM 
products. These models built upon previous studies by Yorobe (2006) for Papaya, 
Mamaril and Norton (2006) for rice, Mamaril (2005) for tomato, and Francisco (2006) 
for eggplant. The results of their analyses were duplicated. These authors’ models 
assumed small open economies for papaya and rice and closed economies for tomato and 
eggplant. Assumptions in these models were then updated and regulatory costs were 
introduced in addition to research and development costs. The models were run allowing 
basic assumptions to vary, including regulatory costs and the time lags for regulatory 
steps. Assessment of net benefits under various scenarios allowed for calculation of 
opportunity costs associated with regulatory time lags.  
 
Results 
The major activities for which there are significant regulatory costs can be categorized 
into four groups: a) contained laboratory and screen house testing, b) confined field trials, 
c) multi-location field trials, and d) other commercialization costs (Table 4). Based on 
information from the sources described above, total estimated regulatory costs vary from 
$248,500 for papaya to $690,000 for rice (Table 5). The two field trial activities represent 
the majority of the costs. Scientists and other experts projected the time required for each 
step. The number of years for each regulatory activity differs by commodity due to 
factors such as differing stages in which the technologies were received by scientists in   10
the Philippines, and the length of time it takes to obtain one generation of the crop. 
Details for each crop are given in Bayer (2007). Total estimated research costs are similar 
in size to regulatory costs, and vary from $120,000 for papaya (significant research 
results transferred in from abroad) to $890,000 for rice. 
 
Table 4.  Regulatory costs (US$) and time  
  Cost/year Years  Total  cost 
Bt eggplant      
   Containment  90,000  2  180,000 
   Limited field trial  100,000  1  100,000 
   Multi-location field trial  100,000  1  100,000 
   Commercialization costs  95,000  1  95,000 
MVR tomato      
   Containment  90,000  2  180,000 
   Limited field trial  100,000  1  100,000 
   Multi-location field trial  100,000  1  100,000 
   Commercialization costs  95,000  1  95,000 
Bt rice      
   Containment  20,800  1  20,800 
   Limited field trial  446,700  1  446,700 
   Multi-location field trial  105,000  2  210,000 
   Commercialization costs  13,180  1  13,180 
RSV papaya      
   Containment  16,000  3  48,000 
   Limited field trial  43,300  2  86,600 
   Multi-location field trial  41,700  2  82,400 
   Commercialization costs  31,500  1  31,500 
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Table 5.  Basic assumptions in economic surplus models 
  Bt eggplant  MVR tomato  Bt rice  RSV papaya 
Quantity (MTs)  182,750  152,690  10,500,000  159,000 
Price (US$/MT)  200  215  180  363 
Supply Elasticity  .5  .75  .95  .80 
Demand Elasticity  -.80  -.45  -.30  -1.0 
Change in yield %  40  67  2.4  77 
Change in costs %  -16  -10  0  8 
Prob. Of success %  70  50  100  83 
Max adoption %  50  70  66  80 
Years to first adopt  9  12  8  10 
Years to max adopt  14  14  15  15 
Total research cost  $580,000  $434,000  $888,729  $120,370 
Total regulatory cost  $475,000  $475,000  $690,680  $249,500 
 
RSV papaya, MVR tomato and Bt eggplant are being developed and tested by researchers 
and scientists at the University of the Philippines Los Baños. Transformed papaya and 
eggplant are now in confined field trials. It is expected that regulatory costs for MVR 
tomato will follow a similar pattern to that of Bt eggplant. Bt rice has been developed and 
tested at the Philippine Rice Research Institute (PhilRice) located in Nueva Ecija.  Much 
of the regulatory activity on Bt rice occurred over a 3 year period.  Confined screen house 
testing in the first year cost $20,800, while the second year contained field testing cost 
$446,700.  Multi-location field testing is projected to cost $105,000 per year.  
Commercialization and public release were projected to cost $13,180 (Table 4).  
A large set of assumptions is required for am economic surplus analysis, and 
several of the most important ones are listed in table 5. Rice production is substantial in 
the Philippines and adoption of Bt rice is projected to be significant despite a relatively   12
low impact on yield. According to the experts consulted, adoption is projected to be more 
gradual however, than for the other products, perhaps due to the small yield effect. 
Because Bt rice exists and is part way through the regulatory process, the experts were 
confident it would be a successful and gave it a probability of research success of 1. 
MVR tomato is the product that is farthest away from the market.  
The net present value of benefits minus costs over 20 years, beginning from 
inception of the research (discounted at 5%), varied from $17 million for tomato, to 
$20milion for eggplant, to $220 million for rice, to $90 million for papaya (Table 6). A 
variety of sensitivity analyses were conducted, such as varying the elasticity of supply 
and the discount rate. They had predictable effects on benefits, such as smaller supply 
elasticity or a smaller discount rate increasing benefits significantly. 
 
Table 6. Economic surplus results (US$) 
  Bt eggplant  MVR tomato  Bt rice  RSV papaya 
Total benefits  40,813,627  34,240,196  481,723,200  171,976,074 
Consumer benefits   15,697,549  21,400,122  0  0 
Producer benefits  25,116,078  12,840,073  481,723,200  171,976,074 
NPV of benefits minus 
costs (at 0% Dis. rate) 
39,758,627 33,331,196  480,143,791  171,606,204 
NPV of benefits minus 
costs (at 5% Dis. rate ) 
20,466,196 16,748,347  220,373,603  90,765,793 
 
However, the key sensitivity analyses were to evaluate the effects of increasing 
regulatory costs and altering the time required for regulatory approval and hence adoption 
of the technologies by farmers (Table 7). Even when regulatory costs were doubled or 
quadrupled, effects on total net benefits in each case were small, less than US$1 million   13
change in NPV in most cases. The decrease in the NPV with respect to the baseline, 
varied from a 1% decrease for the rice and papaya technologies, to a 7% decrease in the 
case of MVR tomato.  These losses were small compared to the losses (opportunity costs) 
that were incurred when commercialization was delayed by 1, 2, or 3 years due to 
regulatory delays beyond the expected timeframe (Table 7). In each case, several million 
dollars were lost due to regulatory delay. A one year delay in the onset of benefits 
induced a 12% decrease in the projected NPV for Bt rice and up to a 36% decrease for 
MVR tomato. A three year regulatory delay would decrease the NPV compared to the 
baseline by 34% for Bt rice, and 93% for MVR tomato.  A combined increase in the cost 
of regulations and a regulatory delay would increase losses even more, albeit by a small 
proportion. 
 
Table 7. Sensitivity analysis (NPV of benefits minus costs under varying 
assumptions on regulatory costs and time lags) (US$)(Discount rate = 5%) 
  Bt eggplant  MVR tomato  Bt rice  RSV papaya 
Baseline 20,466,196  16,748,347  220,373,603  90,765,793 
      
Reg. costs          
  75% higher  20,550,612  16,529,580  219,976,847  90,633,007 
  200% higher  20,128,529  16,164,968  219,315,587  90,411,698 
  400% higher  19,435,196  15,581,590  218,257,570  90,097,124 
Reg. time lag         
  1 year longer  14,707,235  10,656,533  193,926,128  66,362,939 
  2 years longer  8,931,527  4,854,806  168,738,056  46,060,500 
  3 years longer  4,242,285  1,110,757  144,749,416  29,540,365 
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The potential sources of regulatory delays include the repetition of tests, review time by 
the NCBP, information requests by regulators, and lack of clarity with respect to the 
requirements of the NCBP.  One example of a factor that can cause a time delay is an 
NCBP request of more information from a previous generation.  Under the containment 
rules of the NCBP, it is required that each generation, Tn, of the plant be destroyed once 
any and all tests are completed and the next generation, Tn+1, has been produced.  In the 
instance of an information request from the T0 generation when the scientists are testing 
the T3 generation, T3 then reverts to being the T0 generation and three more generations 
of the plant must be produced, resulting in a time loss of three growing seasons.  With a 3 
month growing season, the result would be a loss of one year.  In the case of a 1 year 
growing season such as with papaya, the result would be a loss of 3 years.   
The duplication of tests is another potential source of time delay.  An example of 
this is the agro-morphology, or parent to progeny, test that is being duplicated by separate 
tests.  A lack of clarity in terms of regulatory requirements creates time delays by 
encouraging scientists to gather extra information in anticipation of possible later 
requests by the NCBP.  An inherent delay is created by the NCBP review panel schedule, 
as it meets only once a month.  Each time the NCBP requests information about a product 
under review, there is a delay of at least one meeting, implying a delay of at least one 
month.  In many cases this delay can be avoided by the attendance of a researcher at the 
NCBP meeting so he or she can answer questions the panel may have about the product 
that do not require further testing. 
An additional issue with regard to implications of the cost of compliance with 
bio-safety regulations is the potential “barrier to entry” they may create for small private   15
firms and even the public sector in developing countries. The cost of compliance with 
bio-safety regulations may be high enough that it deters a firm or institution from 
pursuing GM technologies, or to abandon or delay commercialization of potentially 
valuable products. Compared to large multinational corporations, neither small firms nor 
the public sector may have the cash flow and budget flexibility to absorb regulatory 
delays, during which financial resources spent on compliance with bio-safety regulations 
are frozen until a regulatory decision is made by the proper authority. For technologies 
that are public goods, especially those that are pro-poor, finding resources to pay for 
regulatory compliance is critical.  
The uncertainty that surrounds a regulatory outcome may also serve as a deterrent 
to public sector institutions or small private forms to consider GM technologies as a 
potential solution to agricultural problems. Innovation may be unnecessarily stifled in a 
particular country unless it is careful to make certain that none of the steps in its 
regulatory process for GM products are trivial or unnecessary.   
 
Conclusion 
The key contributions of this paper are to document the nature and size of regulatory 
costs for different types of genetically modified crops in a developing country setting, 
estimate opportunity costs of delays for comparative purposes, and summarize potential 
impacts of several different transgenic products. The Philippines is an excellent case 
study because the country has several GM products already undergoing the regulatory 
testing and approval process, has already released Bt corn for commercialization, and has 
experience with bio-safety evaluations of commodity imports.    16
A study in India by Pray, Bengali, and Ramaswami previously found private 
regulatory costs for Bt cotton in the neighborhood of $2 million. That study notes, 
however, that public sector regulatory costs can be lower, in part because the private 
sector must contract with the public sector for some of the regulatory steps. Our results 
confirm their hypothesis, with regulatory costs running less than $1 million. Especially 
for products for which many of the basic laboratory bio-safety tests have already been 
completed elsewhere, such as in the RSV papaya case, direct regulatory costs do not 
appear to be prohibitive given the size of the benefits, assuming the benefits can be 
captured by those commercializing the product. Estimates presented in this paper indicate 
that the bigger constraint to release of transgenic products is the risk of regulatory time 
delays, which induces significant reduction in the level of benefits.    
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